CV Sciences Q3 revenue $3.3M (-16% YoY); adjusted EBITDA loss $118K; hemp regulatory language enacted with 1-yr delay

CV Sciences, Inc.

2025-Q3 EPS reported $0.00 revenue$10,482,000

Revenue $3.3M, down 16% YoY from $3.9M; net revenue from products launched since Jan 2023 contributed 39%.
Gross margin 48.5% (Q3 2024: 46.0%; Q2 2025: 50.9%); adjusted EBITDA loss $118K vs $75K loss in Q3 2024.
Cash balance $0.4M at quarter-end; launched +PlusCBD Ignite men's formula. Federal hemp language enacted with one-year delay.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.